HCA Healthcare Reports Fourth Quarter 2021 Results and Provides 2022 Guidance

Go back to HCA Healthcare Reports Fourth Quarter 2021 Results and Provides 2022 Guidance

HCA Holdings (HCA) PT Lowered to $265 at Cowen

January 28, 2022 8:01 AM EST

Cowen analyst Gary Taylor lowered the price target on HCA Holdings (NYSE: HCA) to $265.00 (from $302.00) while maintaining an Outperform rating.

The analyst commented, "HCA model update; slightly lowering EBITDA for 2022/23/24 to $12.810/13.365/14.087b from $12.969/13.527b/na. COVID costs/occupancy, deferred surgical... More

HCA Holdings (HCA) PT Lowered to $250 at BMO Capital

January 28, 2022 7:56 AM EST

BMO Capital analyst Matt Borsch lowered the price target on HCA Holdings (NYSE: HCA) to $250.00 (from $275.00) while maintaining a Market Perform rating.

... More

HCA Holdings (HCA) Misses Q4 EPS by 11c, Offers Guidance

January 27, 2022 7:31 AM EST

HCA Holdings (NYSE: HCA) reported Q4 EPS of $4.42, $0.11 worse than the analyst estimate of $4.53. Revenue for the quarter came in at $15.06 billion versus the consensus estimate of $15.37 billion.

GUIDANCE:

HCA Holdings sees FY2022 EPS of $18.40-$19.20, versus the consensus of... More